Marché Fermé -
Autres places de cotation
|
Après clotûre 01:50:01 | |||
128,7 USD | -0,49 % | 130,5 | +1,43 % |
14/05 | La FDA américaine refuse d'approuver l'utilisation élargie du vaccin contre l'hépatite B de Dynavax | RE |
13/05 | Merck : arrêt d'un essai de phase 3 dans le mélanome | CF |
Métier
- vente de produits pharmaceutiques (69,7%) : destinés au traitement de l'hypertension, de l'ostéoporose, de l'athérosclérose, des maladies respiratoires, bactériennes et fongiques, ophtalmologiques et urologiques, de la migraine aigue, de la perte de cheveux chez l'homme, etc. ;
- vente de vaccins (18%) ;
- vente de produits de santé animale (9,4%) ;
- autres (2,9%).
La répartition géographique du CA est la suivante : Etats-Unis (45,9%), Europe-Moyen Orient-Afrique (24,5%), Chine (8,8%), Japon (6,1%), Asie-Pacifique (6,1%), Amérique latine (4,3%) et autres (4,3%).
Nombre d'employés: 71 000
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Pharmaceutical
89,1
%
| 52 005 | 87,7 % | 53 583 | 89,1 % | +3,03 % |
Animal Health
9,4
%
| 5 550 | 9,4 % | 5 625 | 9,4 % | +1,35 % |
Other
1,5
%
| 1 728 | 2,9 % | 907 | 1,5 % | -47,51 % |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
47,4
%
| 27 206 | 45,9 % | 28 480 | 47,4 % | +4,68 % |
Europe, Middle East and Africa
22,0
%
| 14 493 | 24,4 % | 13 254 | 22,0 % | -8,55 % |
China
11,3
%
| 5 191 | 8,8 % | 6 802 | 11,3 % | +31,03 % |
Asia Pacific
5,4
%
| 3 614 | 6,1 % | 3 225 | 5,4 % | -10,76 % |
Japan
5,3
%
| 3 629 | 6,1 % | 3 164 | 5,3 % | -12,81 % |
Latin America
5,1
%
| 2 582 | 4,4 % | 3 086 | 5,1 % | +19,52 % |
Other
3,5
%
| 2 568 | 4,3 % | 2 104 | 3,5 % | -18,07 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01/04/14 |
Director of Finance/CFO | 55 | 01/01/90 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/08/20 |
Joseph Romanelli
IRC | Investor Relations Contact | 50 | 01/01/96 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 01/07/17 |
Andre Musto
PRN | Corporate Officer/Principal | - | 01/07/14 |
Brooke Hinkson
PRN | Corporate Officer/Principal | - | 01/08/15 |
Carol Bowden
PRN | Corporate Officer/Principal | - | 01/04/14 |
Dalton Smart
AUD | Comptroller/Controller/Auditor | 58 | 01/11/09 |
James Matteucci
PRN | Corporate Officer/Principal | - | 01/01/03 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27/11/07 |
Pamela Craig
BRD | Director/Board Member | 67 | 01/09/15 |
Inge Thulin
BRD | Director/Board Member | 69 | 01/03/18 |
Patricia Russo
BRD | Director/Board Member | 71 | 01/09/95 |
Peter Wendell
BRD | Director/Board Member | 73 | 23/09/03 |
Director/Board Member | 69 | 26/05/20 | |
Robert Davis
CEO | Chief Executive Officer | 57 | 01/04/14 |
Douglas Baker
BRD | Director/Board Member | 65 | 24/05/22 |
Stephen Mayo
BRD | Director/Board Member | 62 | 15/03/21 |
Kathy Warden
BRD | Director/Board Member | 52 | 16/03/20 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 3 577 208 962 | 2 531 406 448 ( 70,76 %) | 1 044 402 655 ( 29,20 %) | 70,76 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
13 443 693 | 10,62% | 289 287 301 $ | |
1 739 768 | 5,17% | 21 503 532 $ | |
XILIO THERAPEUTICS, INC. 4,02% | 1 483 414 | 4,02% | 1 498 248 $ |
EVAXION BIOTECH A/S 12,13% | 2 297 884 | 12,13% | 946 728 $ |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
MSD Regional Business Support Center GmbH
MSD Regional Business Support Center GmbH Miscellaneous Commercial ServicesCommercial Services Part of Merck & Co., Inc., MSD Regional Business Support Center GmbH is a German company that provides management consulting services. The private company is based in Munich, Germany. Jutta König has been the CEO of the company since 2021. |
Miscellaneous Commercial Services
|
Merck Holdings, Inc.
| |
MSD International GmbH (Switzerland)
MSD International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD International GmbH (Switzerland) is a Swiss company that discovers, develops and markets human and animal health products. The private company is located in Switzerland. |
Pharmaceuticals: Major
|
Schering Plough International Finance Co. BV
| |
MSD Human Health Holding BV
MSD Human Health Holding BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD Human Health Holding BV discovers, develops and markets human and animal health products. The private company is based in Oss, Netherlands. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme LLC is a pharmaceutical company. The private company is based in Kenilworth, NJ. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. |
Pharmaceuticals: Major
|
Essex Chemie AG
| |
Merck Sharp & Dohme BV
Merck Sharp & Dohme BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme BV is a Dutch company that manufactures and distributes pharmaceutical products. The private company is based in Haarlem, the Netherlands. |
Pharmaceuticals: Major
|
Secteur
Ventes par activité
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+18,02 % | 327 Md | |
+31,06 % | 682 Md | |
+30,35 % | 586 Md | |
-3,42 % | 364 Md | |
+4,27 % | 285 Md | |
+15,53 % | 240 Md | |
+10,16 % | 209 Md | |
-8,14 % | 203 Md | |
+8,12 % | 165 Md | |
-1,42 % | 161 Md |
- Bourse
- Actions
- Action MRK
- Société Merck & Co., Inc.